Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 11/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30811430 | 1.00 | CNR2 (0.38) | CNR2ACEPREPDPP4FAP | |
| SCHEMBL31590738 | 0.85 | ACE (0.51) | ACEPREPDPP4FAPDPP8 | |
| SCHEMBL7352024 | 0.85 | ACE (0.51) | ACEPREPDPP4FAPDPP8 | |
| SCHEMBL5743175 | 0.84 | CNR2 (0.37) | CNR2ACEPREP | |
| SCHEMBL1021746 | 0.84 | CNR2 (0.37) | CNR2ACEPREP | |
| SCHEMBL28789465 | 0.79 | ACE (0.40) | CNR2ACEPREPDPP4DPP8 | |
| SCHEMBL1022056 | 0.79 | ACE (0.40) | CNR2ACEPREPDPP4DPP8 | |
| SCHEMBL6002706 | 0.79 | ACE (0.40) | CNR2ACEPREPDPP4DPP8 | |
| SCHEMBL7769272 | 0.74 | GAA (0.42) | CNR2ACEPREPDPP4 | |
| SCHEMBL4102086 | 0.73 | ACE (0.35) | CNR2ACEDPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368637-A1 | SOLID-STATE FORMS OF N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-6-MORPHOLINOQUINOLINE-4-CARBOXAMIDE | ASTRAZENECA AB (SE) | 2025-12-04 | — | — | US | disclosed |
| CN-119585266-A | Solid state forms of N- (2- (4-cyanothiazolidin-3-yl) -2-oxoethyl) -6-morpholinoquinoline-4-carboxamide | 阿斯利康(瑞典)有限公司 | 2025-03-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368637-A1 | SOLID-STATE FORMS OF N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-6-MORPHOLINOQUINOLINE-4-CARBOXAMIDE | FAP, FIBP, DNPEP | CNR2 4099/4885ACE 50/4885PREP 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.